A British company's wound-care tests that indicate how likely bacteria are to infect a chronic wound and how likely a wound is to heal may be brought to the U.S. market.
Woundchek Laboratories in Great Britain has teamed up with the U.S.-based SerenaGroup to complete clinical trials of its Woundchek Protease Status test and its Woundchek Bacterial Status test, hoping to gain approval from the U.S. Food and Drug Administration.
The company's bacterial test checks for bacterial activity which can indicate that a wound has become infected and requires intervention. The protease test, which is already available in Europe, tests for elevated protease activity which can indicate how well a chronic wound will heal.
In a press release, Jack Wilkens, CEO and president of Woundchek Laboratories said, "Our vision is to provide clinicians with accurate, timely, actionable, and easy to access information, leading to improved therapeutic outcomes and more cost effective care through point of care wound diagnostics."